Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases

Andrea Visentin, Silvia Imbergamo, Federica Frezzato, Marco Pizzi, Roberta Bertorelle, Edoardo Scomazzon, Tamara Berno, Marcello Riva, Elisa Piva, Monica Facco, Francesco Piazza, Gianpietro Semenzat, Livio Trentin

Research output: Contribution to journalArticlepeer-review

Abstract

Hairy cell leukemia variant (HCLv) is a chronic lymphoproliferative disorder classified as a provisional entity in the 2016 WHO Classification of Lymphoid Tumors. HCLv is characterized by unfavorable prognosis, low complete remission rates and limited disease control following classical hairy cell leukemia-based regimens. In this study, we report 3 cases of elderly patients with treatment-naive, TP53 unmutated HCLv, who were effectively treated with four cycles of bendamustine plus rituximab. The regimen was completed in all the patients with acceptable toxicity. All patients achieved a complete clinical response with no evidence of residual disease at bone marrow biopsy and flow-cytometry examination. After a median follow-up of 19 months, the 3 subjects are still in complete remission. In this work, bendamustine plus rituximab proved to be an effective and feasible first-line treatment strategy for elderly patients with TP53 un-mutated HCLv.

Original languageEnglish
Pages (from-to)110727-110731
Number of pages5
JournalOncotarget
Volume8
Issue number66
DOIs
Publication statusPublished - Jan 1 2017

Keywords

  • Bendamustine
  • BR
  • HCL
  • HCL variant
  • Treatment naive

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases'. Together they form a unique fingerprint.

Cite this